Paul R. Rosie

Paul Rosie, a partner in Goodwin’s Life Sciences group, has extensive experience guiding companies through the entire corporate lifecycle, including pre-incorporation planning, seed, venture capital and growth financings, mergers and acquisitions, public offerings, and SEC compliance. Paul focuses on the life sciences and technology industries, including AI, biotechnology, cybersecurity, digital health, medtech, and robotics. He also counsels venture capital firms in connection with venture and growth equity investments.

Mergers and Acquisitions

• Abide Therapeutics in its sale to Lundbeck
• Allurion Technologies in its business combination with Compute Health Acquisition Corp.
• Bend Financial in its sale to Webster Financial Corporation
• COTA in its merger with Verana Health*
• HealthEdge in its sale to Blackstone
• Helio Vision in its sale to Aldeyra Therapeutics
• iRobot Corporation in its acquisitions of Aeris Cleantec AG and Robopolis SAS
• Meilleur Technologies in its sale to Lantheus Holdings
• Mitralign in its sale to Edward Lifesciences Corporation
• Moxe Health in its majority investment by BV Investment Partners*
• Noetic Cyber in its sale to Rapid7

Venture Financings

• Allurion Technologies in its preferred stock financings
• Arccos Golf in its $20 million Series C financing
• COTA in its equity and debt financings
• Health Data Analytics Institute in its $31 million Series C financing
• Labviva in its $20 million Series A financing and $25 million Series B financing
• Outcomes4Me in its $12 million Series A financing
• Tomorrow.io in its preferred stock financings, including its $87 million Series E financing
• Zus Health in its $34 million Series A financing

Public Offerings

• Allurion Technologies in its $20 million follow-on offering
• BeiGene, Ltd. in its $200 million, $201 million and $800 million follow-on public offerings
• Underwriters in Flywire’s $256 million follow-on public offering
• Underwriters in Ibex Limited’s $90 million initial public offering
• Underwriters in Oscar Health’s $1.4 billion initial public offering

*Denotes experience outside of Goodwin.

Paul began his career at Goodwin in 2015. Before that, he served as senior corporate counsel at athenahealth, where he advised on corporate governance and securities matters, mergers and acquisitions, and the launch of its innovation and partnership program.